U.S. Solid Tumor Testing Market - A Country Analysis: Focus on Technology, Cancer Type, Type of Biomarker, By Application, by End User, and Region - Analysis and Forecast, 2022-2032
U.S. Solid Tumor Testing Market Industry Overview
The U.S. solid tumor testing market was estimated to be at $9,498.8 million in 2021, which is expected to grow with a CAGR of 6.19% during the forecast period 2022-2032 and reach $18,287.6 million by 2032. The growth in the U.S. solid tumor testing market is expected to be driven by increasing awareness of early tumor diagnosis and tests along with the increasing geriatric population. Furthermore, increasing cancer incidences in the pediatric population.
Market Lifecycle Stage
The U.S. solid tumor testing market is progressing rapidly. Significant increases in the research and development activities pertaining to solid tumor testing are underway to develop better testing kits and assays, which are expected to increase due to the rising frequency and efficiency of cancer testing products. The recent allocation of $6.44 billion to NCI in FY2019, as per the Department of Health and Human Services Appropriations Act and the 21st Century Cures Act, has further brightened the prospects for key players to bring a diagnostic or therapeutic innovation to the market with conditional support (pertaining to innovation or diagnostic/therapeutic breakthrough and a relative grant triggered from NCI).
Impact
The presence of major service providers of solid tumor testing in the U.S. has a major impact on the market. For instance, Illumina, Inc. acquired GRAIL which is a cancer detection healthcare company. With this acquisition, Illumina, Inc. can accelerate the adoption of this lifesaving Galleri blood test worldwide which is known to detect 50 different cancer types.
Companies such as QIAGEN partnered with PGDx for molecular cancer testing. With the help of this, laboratories will be able to receive standardized reporting from QIAGEN and receive access to QIAGEN’s QCI Interpret One for rapid next-generation sequencing tests.
Impact of COVID-19
It is known that people with cancer are more susceptible to infectious agents due to their impaired immune systems. However, this was found inconsistent with COVID-19. The very early studies found that people with cancer are more susceptible to COVID-19 and its severe complications, especially for patients with lung or hematological cancers. However, some of the most recent, larger studies found no increased risk of death due to cancer type or timing of cancer treatment.
There were numerous consequences due to the COVID-19 pandemic, especially because of the reduced access to care for other illnesses. As the number of individuals becoming ill from COVID-19 kept increasing and for the protection of healthy individuals from being affected by the disease, all non-urgent healthcare facilities were suspended in the U.S. by the recommendation of the American Cancer Society and other organizations. Even though these measures were necessary, they led to delays in cancer diagnosis, screening, and treatment. This led to increased later-stage cancer diagnoses and, in turn, cancer deaths that may have been preventable.
Market Segmentation:
Segmentation 1: by Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In-Situ Hybridization
Immunohistochemistry
Liquid Chromatography/Mass Spectrometry
Other Technologies
Based on technology, the U.S. solid tumor testing market is expected to be dominated by the next-generation sequencing technology. This is due to the high accuracy and efficiency of next-generation sequencing techniques.
Segmentation 2: by Cancer Type
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Melanoma
Endometrial Cancer
Lymphoma
Thyroid Cancer
Brain Cancer
Other Cancer Types
Based on cancer type, the U.S. solid tumor testing market is dominated by breast cancer, owing to an increasing number of patients suffering from breast cancer and also more awareness and better diagnosis of cancer.
Segmentation 3: by Type of Biomarker
Genetic Biomarker
Molecular Biomarker
Cellular Biomarker
Imaging Biomarker
Protein Biomarker
Predisposition Biomarker
Diagnostic Biomarker
Prognostic Biomarker
Predictive Biomarker
The genetic biomarkers segment dominates the U.S. solid tumor testing market; however, the protein biomarkers segment shows the largest CAGR of 6.61%. The growth in this segment is mainly due to the growth in research and development, which is leading to the discovery of more biomarkers.
Segmentation 4: by Application
Clinical
Diagnostics
Treatment and Monitoring
Screening
Prognosis
Research
Biomarker Discovery
Personalized Medicine
The clinical application dominated the application segment. This is because the solid tumor testing market is already well established with many clinical applications. However, the research segment has a higher CAGR of 6.61% as compared to 5.92% for clinical and is expected to grow at a fast pace during the forecast period. Research has increased due to the emergence of personalized medicine.
Segmentation 5: by End User
Hospitals
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic Research Institutions
Other End Users
Hospitals dominated the end-user segment. This is due to an increasing number of oncologists playing a key role in the recommendation and data interpretation of solid tumor tests. Due to this, most tests are performed through the hospitals, thereby making it a dominating segment of the market and its growth.
Segmentation 6: by Region
The Southern U.S.
The Midwest U.S.
The Mid-Atlantic U.S.
The West U.S.
The Southwest U.S.
New England
The Southern U.S. dominated the regions with a revenue of $2,614.7 in 2021. The high incidence of cancer in a few states like California, Florida, and Texas are the key areas for solid tumor testing market growth.
Recent Developments in U.S. Solid Tumor Testing Market
In December 2021, Opko Health, Inc. secured FDA approval for its 4Kscore test that is approved for men 45 years or older who haven’t had a prior prostate biopsy or are biopsy negative.
In April 2021, NeoGenomics Laboratories. launched biomarker assist KRAS single gene test. This test is used for advanced or metastatic small cell lung cancer patients.
In November 2020, NeoGenomics Laboratories. started mobile phlebotomy services for liquid biopsy tests. These tests include InVisionFirst-Lung, which is a non-small cell lung liquid biopsy test, and the NeoLab liquid biopsy test, which is used for all solid tumors and hematological cancers.
In February 2020, QIAGEN obtained a CE mark for its therascreen PIK3CA mutation assay. This test can be used to identify breast cancer.
Demand – Drivers and Limitations
Following are the demand drivers for the U.S. solid tumor testing market
Rising Advancements in Solid Tumor Testing and Rapid Usage of Liquid Biopsy
Early Cancer Detection with Multi-Cancer Tests
Increasing Adoption of Inorganic Growth Strategies in the Market
Spike Increase in the Research Funding from National Cancer Institute
Rapid Adoption of Genetic Testing
The market is expected to face some limitations too due to the following challenges:
Reimbursement Cuts in the U.S.
High Pricing Pressure
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The report considers both the product-based and the service-based companies. Since tumor testing is a service, most of the companies considered are service based. However, technologies such as NGS, PCR, and IHC, that are involved in the testing process of solid tumors are also discussed in detail.
Growth/Marketing Strategy: The key components in solid tumor testing consist of kits and assays, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis taking into account the main technologies that are used in testing.
Competitive Strategy: Key players in the U.S. solid tumor testing market were analyzed and profiled in the study, consisting of both product-based and service-based companies as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the U.S. solid tumor testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top segment players leading the market include solid tumor testing service givers that capture around 70% of the presence in the market, and solid tumor testing product manufacturers contribute around 30% of the presence in the market as of 2021
Some of the prominent established names in this market are:
Abbott.
ARUP Laboratories
Bio-Rad Laboratories, Inc.
Caris Life Sciences.
F. Hoffmann-La Roche Ltd
Genomic Testing Cooperative
Guardant Health
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Invitae Corporation
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
NanoString
NeoGenomics Laboratories
Opko Health, Inc.
QIAGEN
Quest Diagnostics Incorporated.
Thermo Fisher Scientific, Inc.
VYANTbio.
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Market
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion
- 1.1.2 Scope of Work
- 1.2 Market Overview
- 1.2.1 Solid Tumor Testing Workflow
- 1.3 Significant Technologies
- 1.4 Industry Participants Landscape
- 1.5 Epidemiology of Solid Tumors in the U.S.
- 1.5.1 Southern U.S.
- 1.5.2 Midwest U.S.
- 1.5.3 Mid-Atlantic U.S.
- 1.5.4 West U.S.
- 1.5.5 Southwest U.S.
- 1.5.6 New England
- 1.6 Future Potential
- 2 Industry Insights
- 2.1 Patent Analysis
- 2.1.1 Patent Filing Trend
- 2.1.1.1 Patent Analysis (by Year)
- 2.2 Legal Requirements
- 2.2.1 Regulation of Genetic Tests
- 2.2.1.1 The U.S. FDA Regulations
- 2.2.1.2 CMS Regulation
- 2.2.2 Reimbursement Scenario
- 2.2.2.1 Impact on Laboratory Analysis
- 3 Market Dynamics
- 3.1 Overview
- 3.1.1 Market Drivers
- 3.1.1.1 Rising Advancements in Solid Tumor Testing and Rapid Usage of Liquid Biopsy
- 3.1.1.2 Early Cancer Detection with Multi-Cancer Tests
- 3.1.1.3 Increasing Adoption of Inorganic Growth Strategies in the Market
- 3.1.1.4 Spike Increase in the Research Funding from National Cancer Institute
- 3.1.1.5 Rapid Adoption of Genetic Testing
- 3.1.2 Market Restraints
- 3.1.2.1 Reimbursement Cuts in the U.S.
- 3.1.2.2 High Pricing Pressure
- 3.1.3 Market Opportunities
- 3.1.3.1 Technological Innovation for Larger Consumer Base and Role of Informatics
- 3.1.3.2 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
- 3.2 COVID-19 Impact on U.S. Solid Tumor Testing Market
- 4 Competitive Landscape
- 4.1 Competitive Landscape
- 4.1.1 Acquisitions
- 4.1.2 Synergistic Activities
- 4.1.3 Product Launches and Upgradations
- 4.1.4 Business Expansion
- 4.1.5 Fundings
- 4.1.6 Market Share Analysis (2020 and 2021)
- 4.1.7 Growth-Share Analysis (2021)
- 4.1.7.1 Growth-Share Analysis by Technology
- 4.1.7.2 Growth-Share Analysis by Biomarker Type
- 4.1.7.3 Growth-Share Analysis by Application
- 4.2 Supply Chain Analysis
- 4.3 Pricing Analysis (by Technology)
- 5 U.S. Solid Tumor Testing Market, by Technology, $Million, 2021 - 2032
- 5.1 Overview
- 5.1.1 Next-Generation Sequencing
- 5.1.2 Polymerase Chain Reaction
- 5.1.3 Fluorescence In-Situ Hybridization
- 5.1.4 Immunohistochemistry (IHC)
- 5.1.5 Liquid Chromatography/Mass Spectrometry
- 5.1.6 Other Technologies
- 6 U.S. Solid Tumor Testing Market, by Cancer Type, By Value ($Million), 2021-2032
- 6.1 Overview
- 6.1.1 Breast Cancer
- 6.1.2 Prostate Cancer
- 6.1.3 Colorectal Cancer
- 6.1.4 Lung Cancer
- 6.1.5 Melanoma
- 6.1.6 Endometrial Cancer
- 6.1.7 Lymphoma
- 6.1.8 Thyroid Cancer
- 6.1.9 Brain Cancer
- 6.1.10 Other Cancer Types
- 7 U.S. Solid Tumor Testing Market, by Type of Biomarker, By Value ($Million), 2021-2032
- 7.1 Overview
- 7.1.1 Genetic Biomarker
- 7.1.1.1 Molecular Biomarker
- 7.1.1.2 Cellular Biomarker
- 7.1.1.3 Imaging Biomarker
- 7.1.2 Protein Biomarker
- 7.1.2.1 Diagnostic Biomarker
- 7.1.2.2 Prognostic Biomarker
- 7.1.2.3 Predictive Biomarker
- 7.1.2.4 Predisposition Biomarker
- 8 U.S. Solid Tumor Testing Market, by Application, By Value ($Million), By Volume (Units), 2021-2032
- 8.1 Overview
- 8.1.1 Clinical
- 8.1.1.1 Diagnostics
- 8.1.1.2 Treatment and Monitoring
- 8.1.1.3 Screening
- 8.1.1.4 Prognosis
- 8.1.2 Research
- 8.1.2.1 Biomarker Discovery
- 8.1.2.2 Personalized Medicine
- 9 U.S. Solid Tumor Testing Market, by End-User, By Value ($Million), By Volume (Units), 2021-2032
- 9.1 Overview
- 9.1.1 Hospitals
- 9.1.2 Pharmaceutical and Biotechnology Companies
- 9.1.3 Contract Research Organizations
- 9.1.4 Academic Research Institutes
- 9.1.5 Other End Users
- 10 U.S. Solid Tumor Testing Market, by Region, $Million, 2021-2032
- 10.1 Overview
- 10.1.1 Southern U.S.
- 10.1.2 Midwest U.S.
- 10.1.3 Mid-Atlantic U.S.
- 10.1.4 West U.S.
- 10.1.5 Southwest U.S.
- 10.1.6 New England
- 11 Market - Competitive Benchmarking & Company Profiles
- 11.1 Overview
- 11.1.1 U.S. Solid Tumor Testing Value Chain
- 11.2 Abbott.
- 11.2.1 Company Overview
- 11.2.2 Role of Abbott. in the U.S. Solid Tumor Testing Market
- 11.2.3 Key Customers of the Company
- 11.2.4 Key Competitors of the Company
- 11.2.5 Financials
- 11.2.6 Key Insights about the Financial Health of the Company
- 11.2.7 Analyst Perspective
- 11.3 ARUP Laboratories.
- 11.3.1 Company Overview
- 11.3.2 Role of ARUP Laboratories. in the U.S. Solid Tumor Testing Market
- 11.3.3 Key Customers of the Company
- 11.3.4 Key Competitors of the Company
- 11.3.5 Corporate Strategies
- 11.3.6 Analyst Perspective
- 11.4 Bio-Rad Laboratories, Inc.
- 11.4.1 Company Overview
- 11.4.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
- 11.4.3 Key Customers of the Company
- 11.4.4 Key Competitors of the Company
- 11.4.5 Financials
- 11.4.6 Key Insights about the Financial Health of the Company
- 11.4.7 Analyst Perspective
- 11.5 Caris Life Sciences.
- 11.5.1 Company Overview
- 11.5.2 Role of Caris Life Sciences. in the U.S. Solid Tumor Testing Market
- 11.5.3 Key Customers of the Company
- 11.5.4 Key Competitors of the Company
- 11.5.5 Corporate Strategies
- 11.5.6 Analyst Perspective
- 11.6 F. Hoffmann-La Roche Ltd
- 11.6.1 Company Overview
- 11.6.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
- 11.6.3 Key Customers of the Company
- 11.6.4 Key Competitors of the Company
- 11.6.5 Business Strategies
- 11.6.6 Financials
- 11.6.7 Key Insights About Financial Health of the Company
- 11.6.8 Analyst Perspective
- 11.7 Genomic Testing Cooperative
- 11.7.1 Company Overview
- 11.7.2 Role of Genome Testing Cooperative in the U.S. Solid Tumor Testing Market
- 11.7.3 Key Competitors of the Company
- 11.7.4 Business Strategies
- 11.7.5 Analyst Perspective
- 11.8 Guardant Health
- 11.8.1 Company Overview
- 11.8.2 Role of Guardant Health in the U.S. Solid Tumor Testing Market
- 11.8.3 Key Competitors of the Company
- 11.8.4 Key Customers of the Company
- 11.8.5 Business Strategies
- 11.8.6 Corporate Strategies
- 11.8.7 Financials
- 11.8.8 Key Insights about the Financial Health of the Company
- 11.8.9 Analyst Perspective
- 11.9 HTG Molecular Diagnostics, Inc.
- 11.9.1 Company Overview
- 11.9.2 Role of HTG Molecular Diagnostics, Inc. in the U.S. Solid Tumor Testing Market
- 11.9.3 Key Competitors of the Company
- 11.9.4 Financials
- 11.9.5 Key Insights about the Financial Health of the Company
- 11.9.6 Analyst Perspective
- 11.1 Illumina, Inc.
- 11.10.1 Company Overview
- 11.10.2 Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
- 11.10.3 Key Competitors of the Company
- 11.10.4 Key Customers of the Company
- 11.10.5 Corporate Strategies
- 11.10.6 Financials
- 11.10.7 Key Insights about the Financial Health of the Company
- 11.10.8 1.1.7 Analyst Perspective
- 11.11 Invitae Corporation.
- 11.11.1 Company Overview
- 11.11.2 Role of Invitae Corporation. in the U.S. Solid Tumor Testing Market
- 11.11.3 Key Competitors of the Company
- 11.11.4 Key Customers of the Company
- 11.11.5 Corporate Strategies
- 11.11.6 Business Strategies
- 11.11.7 Financials
- 11.11.8 Key Insights about the Financial Health of the Company
- 11.11.9 Analyst Perspective
- 11.12 Invivoscribe, Inc.
- 11.12.1 Company Overview
- 11.12.2 Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
- 11.12.3 Key Competitors of the Company
- 11.12.4 Analyst Perspective
- 11.13 Laboratory Corporation of America Holdings.
- 11.13.1 Company Overview
- 11.13.2 Role of Laboratory Corporation of America Holdings. in the U.S. Solid Tumor Testing Market
- 11.13.3 Key Competitors of the Company
- 11.13.4 Key Customers of the Company
- 11.13.5 Corporate Strategies
- 11.13.6 Business Strategies
- 11.13.7 Financials
- 11.13.8 Analyst Perspective
- 11.14 NanoString.
- 11.14.1 Company Overview
- 11.14.2 Role of NanoString. in the U.S. Solid Tumor Testing Market
- 11.14.3 Key Customers of the Company
- 11.14.4 Key Competitors of the Company
- 11.14.5 Corporate Strategies
- 11.14.6 Financials
- 11.14.7 Analyst Perspective
- 11.15 NeoGenomics Laboratories.
- 11.15.1 Company Overview
- 11.15.2 Role of NeoGenomics Laboratories. in the U.S. Solid Tumor Testing Market
- 11.15.3 Key Competitors of the Company
- 11.15.4 Corporate Strategies
- 11.15.5 Business Strategies
- 11.15.6 Financials
- 11.15.7 Key Insights about the Financial Health of the Company
- 11.15.8 Analyst Perspective
- 11.16 Opko Health, Inc.
- 11.16.1 Company Overview
- 11.16.2 Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
- 11.16.3 Key Customers of the Company
- 11.16.4 Key Competitors of the Company
- 11.16.5 Business Strategies
- 11.16.6 Financials
- 11.16.7 Key Insights about the Financial Health of the
- 11.16.8 Analyst Perspective
- 11.17 QIAGEN
- 11.17.1 Company Overview
- 11.17.2 Role of QIAGEN in the U.S. Solid Tumor Testing Market
- 11.17.3 Key Customers of the Company
- 11.17.4 Key Competitors of the Company
- 11.17.5 Corporate Strategies
- 11.17.6 Business Strategies
- 11.17.7 Financials
- 11.17.8 Key Insights about the Financial Health of the
- 11.17.9 Analyst Perspective
- 11.18 Quest Diagnostics Incorporated.
- 11.18.1 Company Overview
- 11.18.2 Role of Quest Diagnostics Incorporated. in the U.S. Solid Tumor Testing Market
- 11.18.3 Key Customers of the Company
- 11.18.4 Key Competitors of the Company
- 11.18.5 Corporate Strategies
- 11.18.6 Business Strategies
- 11.18.7 Financials
- 11.18.8 Analyst Perspective
- 11.19 Thermo Fisher Scientific, Inc.
- 11.19.1 Company Overview
- 11.19.2 Role of Thermo Fisher Scientific, Inc. in the U.S. Solid Tumor Testing Market
- 11.19.3 Key Customers of the Company
- 11.19.4 Key Competitors of the Company
- 11.19.5 Business Strategies
- 11.19.6 Financials
- 11.19.7 Key Insights about the Financial Health of the Company
- 11.19.8 Analyst Perspective
- 11.2 VYANTbio.
- 11.20.1 Company Overview
- 11.20.2 Role of VYANTbio. in the U.S. Solid Tumor Testing Market
- 11.20.3 Key Competitors of the Company
- 11.20.4 Corporate Strategies
- 11.20.5 Financials
- 11.20.6 Analyst Perspective
- 11.21 Emerging Companies
- 11.21.1 OncXerna Therapeutics
- 11.21.2 PathAI
- 11.21.3 Century Therapeutics
- 11.21.4 Arcus Biosciences
- 11.21.5 OncoMed Pharmaceuticals
- 11.21.6 ALX Oncology
- List of Figures
- Figure 1: Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
- Figure 2: U.S. Solid Tumor Testing Market (by Technology), $Million, 2021 and 2032
- Figure 3: U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2021 and 2032
- Figure 4: U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2021 and 2032
- Figure 5: U.S. Solid Tumor Testing Market (by Application Type), $Million, 2021 and 2032
- Figure 6: U.S. Solid Tumor Testing Market (by End User), $Million, 2021 and 2032
- Figure 7: U.S. Solid Tumor Testing Market Research Methodology
- Figure 8: U.S. Solid Tumor Testing Market: Segmentation
- Figure 9: Solid Tumor Testing Workflow
- Figure 10: Types of Solid Tumors
- Figure 11: Estimated Percent of New Cancer Cases (by Sex), U.S., 2022
- Figure 12: Expected Cancers Cases in the U.S. (by State), 2022
- Figure 13: Relative Number of Expected Cancers Cases (by State), 2022
- Figure 14: Relative Percent of Expected Cancers Cases (by Region), 2022
- Figure 15: Estimated Number of New Cancer Cases by State in Southern U.S. (%), 2022
- Figure 16: Estimated Number of New Cancer Cases by State in Midwest U.S. (%), 2022
- Figure 17: Estimated Number of New Cancer Cases by State in Mid-Atlantic U.S. (%), 2022
- Figure 18: Estimated Number of New Cancer Cases by State in West U.S., (%), 2022
- Figure 19: Estimated Number of New Cancer Cases by State in Southwest U.S. (%), 2022
- Figure 20: Estimated Number of New Cancer Cases by State in New England (%) 2022
- Figure 21: Year-Wise Analysis of Patents Related to Solid Tumor Testing, January 2019-May 2022
- Figure 22: Reimbursement Components in the U.S.
- Figure 23: U.S. Solid Tumor Testing Market - Market Dynamics
- Figure 24: Tissue Biopsy vs. Liquid Biopsy
- Figure 25: Synergistic Activities, 2019-2021
- Figure 26: SBIR and STTR Grants and Contract Funding, 2008-2018
- Figure 27: NCI Fiscal Budget Year on Year, 2013-2018
- Figure 28: Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
- Figure 29: National Expenditures for Medical Services Related to Cancer Care Estimates by Cancer Site and Year (Billions of Dollars)
- Figure 30: Key Players Offering
- Figure 31: COVID-19 Impact
- Figure 32: Share of Key Developments and Strategies, January 2019-April 2022
- Figure 33: Share of Acquisitions (by Company), January 2019-April 2022
- Figure 34: Synergistic Activities Share (by Company), January 2019-April 2022
- Figure 35: Product Launches and Upgradations (by Company), January 2019-April 2022
- Figure 36: Share of Business Expansion Activities (by Company), January 2019-April 2022
- Figure 37: Share of Funding Activities (by Company), January 2019-April 2022
- Figure 38: Market Share Analysis for U.S. Solid Tumor Testing Market, (by Services), $Million, 2020 and 2021
- Figure 39: Growth-Share Analysis of the U.S. Solid Tumor Testing Market (by Technology), 2021
- Figure 40: Growth-Share Matrix for U.S. Solid Tumor Testing Market (by Biomarker Type), 2021
- Figure 41: Growth-Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2021
- Figure 42: Supply Chain Analysis of the U.S. Solid Tumor Testing Market
- Figure 43: U.S. Solid Tumor Testing Market (by Technology)
- Figure 44: Share of U.S. Solid Tumor Testing Market (by Technology), $Million, 2020 and 2031
- Figure 45: U.S. Solid Tumor Testing Market, 000’ Units, 2021-2032
- Figure 46: U.S. Solid Tumor Testing Market (Next-Generation Sequencing), 2021-2032
- Figure 47: U.S. Solid Tumor Testing Market (Next-Generation Sequencing), 000’ Units, 2021-2032
- Figure 48: U.S. Solid Tumor Testing Market (Polymerase Chain Reaction), $Million, 2021-2032
- Figure 49: U.S. Solid Tumor Testing Market (Polymerase Chain Reaction), 000’ Units, 2021-2032
- Figure 50: U.S. Solid Tumor Testing Market (Fluorescence In-Situ Hybridization), $Million, 2021-2032
- Figure 51: U.S. Solid Tumor Testing Market (Fluorescence In-Situ Hybridization), 000’ Units, 2021-2032
- Figure 52: U.S. Solid Tumor Testing Market (Immunohistochemistry), 2021-2032
- Figure 53: U.S. Solid Tumor Testing Market (Immunohistochemistry), 000’ Units, 2021-2032
- Figure 54: U.S. Solid Tumor Testing Market (Liquid Chromatography/Mass Spectrometry), 2021-2032
- Figure 55: U.S. Solid Tumor Testing Market (Liquid Chromatography/Mass Spectrometry), 000’ Units, 2021-2032
- Figure 56: U.S. Solid Tumor Testing Market (Other Technologies), 2021-2032
- Figure 57: U.S. Solid Tumor Testing Market (Other Technologies), 000’ Units, 2021-2032
- Figure 58: U.S. Solid Tumor Testing Market (by Cancer Types)
- Figure 59: Share of U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2021 and 2032
- Figure 60: National Cancer Care Expenditure Estimates (by Cancer Site and Year), $Billion
- Figure 61: Net Patient Economic Burden Associated with Cancer in the U.S. in 2019 (in Millions)
- Figure 62: U.S. Solid Tumor Testing Market (by Cancer Type), 2021-2032
- Figure 63: Estimated New Cancer Cases and Deaths for Breast Cancer, 2022
- Figure 64: U.S. Solid Tumor Testing Market (Breast Cancer), $Million, 2021-2032
- Figure 65: Estimated New Cancer Cases and Deaths for Prostate Cancer, 2022
- Figure 66: U.S. Solid Tumor Testing Market (Prostate Cancer), $Million, 2021-2032
- Figure 67: Estimated New Cancer Cases and Deaths for Colorectal Cancer, 2022
- Figure 68: U.S. Solid Tumor Testing Market (Colorectal Cancer), $Million, 2021-2032
- Figure 69: Estimated New Cancer Cases and Deaths for Lung and Bronchus Cancer, 2022
- Figure 70: U.S. Solid Tumor Testing Market (Lung Cancer), $Million, 2021-2032
- Figure 71: Estimated New Cancer Cases and Deaths for Melanoma of the Skin, 2022
- Figure 72: U.S. Solid Tumor Testing Market (Melanoma), $Million, 2021-2032
- Figure 73: Estimated New Cancer Cases and Deaths for Endometrial Cancer (Uterine Cancer), 2022
- Figure 74: U.S. Solid Tumor Testing Market (Endometrial Cancer), $Million, 2021-2032
- Figure 75: Estimated New Cancer Cases and Deaths for Non-Hodgkin's Lymphoma, 2022
- Figure 76: U.S. Solid Tumor Testing Market (Lymphoma), $Million, 2021-2032
- Figure 77: Estimated New Cancer Cases and Deaths for Thyroid Cancer, 2022
- Figure 78: U.S. Solid Tumor Testing Market (Thyroid Cancer), $Million, 2021-2032
- Figure 79: Estimated New Cancer Cases and Deaths for Brain and Other Nervous System Cancer, 2022
- Figure 80: U.S. Solid Tumor Testing Market (Brain Cancer), $Million, 2021-2032
- Figure 81: U.S. Solid Tumor Testing Market (Other Cancer Types), $Million, 2021-2032
- Figure 82: U.S. Solid Tumor Testing Market (by Type of Biomarker)
- Figure 83: Share of U.S. Solid Tumor Testing Market (by Type of Biomarker), $Million, 2021 and 2032
- Figure 84: Technologies and Data Types for Genetic Biomarker Discovery
- Figure 85: U.S. Solid Tumor Testing Market (Genetic Biomarker), $Million, 2021-2032
- Figure 86: U.S. Solid Tumor Testing Market (by Genetic Biomarker), $Million, 2021 and 2032
- Figure 87: U.S. Solid Tumor Testing Market (Molecular Biomarker), $Million, 2021-2032
- Figure 88: U.S. Solid Tumor Testing Market (Cellular Biomarker), $Million, 2021-2032
- Figure 89: U.S. Solid Tumor Testing Market (Imaging Biomarker), $Million, 2021-2032
- Figure 90: Development of Imaging Biomarkers
- Figure 91: Technologies and Data Types for Protein Biomarker Discovery
- Figure 92: U.S. Solid Tumor Testing Market (Protein Biomarker), $Million, 2021-2032
- Figure 93: U.S. Solid Tumor Testing Market (by Protein Biomarker), $Million, 2021 and 2032
- Figure 94: U.S. Solid Tumor Testing Market (Diagnostic Biomarker), $Million, 2021-2032
- Figure 95: U.S. Solid Tumor Testing Market (Prognostic Biomarker), $Million, 2021-2032
- Figure 96: U.S. Solid Tumor Testing Market (Predictive Biomarker), $Million, 2021-2032
- Figure 97: U.S. Solid Tumor Testing Market (Predisposition Biomarker), $Million, 2021-2032
- Figure 98: U.S. Solid Tumor Testing Market (by Application)
- Figure 99: U.S. Solid Tumor Testing Market (by Application), $Million, 2021 and 2032
- Figure 100: U.S. Solid Tumor Testing Market (Clinical), $Million, 2021-2032
- Figure 101: U.S. Solid Tumor Testing Market (Clinical), $Million, 2021 and 2032
- Figure 102: U.S. Solid Tumor Testing Market (Clinical), 000’ Units, 2021-2032
- Figure 103: U.S. Solid Tumor Testing Market (Diagnostics), $Million, 2021-2032
- Figure 104: U.S. Solid Tumor Testing Market (Treatment and Monitoring), $Million, 2021-2032
- Figure 105: U.S. Solid Tumor Testing Market (Screening), $Million, 2021-2032
- Figure 106: U.S. Solid Tumor Testing Market (Prognosis), $Million, 2021-2032
- Figure 107: U.S. Solid Tumor Testing Market (Research), $Million, 2021-2032
- Figure 108: U.S. Solid Tumor Testing Market (by Research), $Million, 2021 and 2032
- Figure 109: U.S. Solid Tumor Testing Market (Research), 000’ Units, 2021-2032
- Figure 110: U.S. Solid Tumor Testing Market (Biomarker Discovery), $Million, 2021-2032
- Figure 111: U.S. Solid Tumor Testing Market (Personalized Medicine), $Million, 2021-2032
- Figure 112: U.S. Solid Tumor Testing Market (by End User)
- Figure 113: Share of U.S. Solid Tumor Testing Market (by End User), $Million, 2021 and 2032
- Figure 114: U.S. Solid Tumor Testing Market (Hospitals), $Million, 2021-2032
- Figure 115: U.S. U.S. Solid Tumor Testing Market (Hospitals), 000’ Units, 2021-2032
- Figure 116: U.S. Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
- Figure 117: U.S. Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), 000’ Units, 2021-2032
- Figure 118: U.S. Solid Tumor Testing Market (Contract Research Organizations), $Million, 2021-2032
- Figure 119: U.S. Solid Tumor Testing Market (Contract Research Organizations), 000’ Units, 2021-2032
- Figure 120: U.S. Solid Tumor Testing Market (Academic Research Institutes), $Million, 2021-2032
- Figure 121: U.S. Solid Tumor Testing Market (Academic Research Institutes), 000’ Units, 2021-2032
- Figure 122: U.S. Solid Tumor Testing Market (Other End Users), $Million, 2021-2032
- Figure 123: U.S. Solid Tumor Testing Market (Other End Users), 000’ Units, 2021-2032
- Figure 124: U.S. Solid Tumor Testing Market (Region), $Million, 2021-2032
- Figure 125: Cancer Mortality by State in 2020
- Figure 126: Southern U.S. Solid Tumor Testing Market, $Million, 2021-2032
- Figure 127: Midwest U.S. Solid Tumor Testing Market, $Million, 2021-2032
- Figure 128: Mid-Atlantic U.S. Solid Tumor Testing Market, $Million, 2021-2032
- Figure 129: West U.S. Solid Tumor Testing Market, $Million, 2021-2032
- Figure 130: Southwest U.S. Solid Tumor Testing Market, $Million, 2021-2031
- Figure 131: New England Solid Tumor Testing Market, $Million, 2021-2032
- Figure 132: U.S. Solid Tumor Testing Market (Other Technologies), 2021-2032
- Figure 133: U.S. Solid Tumor Testing Market (Other Technologies), Units, 2021-2032
- Figure 134: Total Number of Companies Profiled
- Figure 135: U.S. Solid Tumor Testing Market Value Chain
- Figure 136: Abbott.: Overall Product Portfolio
- Figure 137: Abbott.: Overall Financials, 2019-2021
- Figure 138: Abbott.: Revenue (by Segment), 2019-2021
- Figure 139: Abbott.: Revenue (by Region), 2019-2021
- Figure 140: Abbott.: R&D Expenditure, 2019-2021
- Figure 141: ARUP Laboratories.: Overall Product Portfolio
- Figure 142: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 143: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
- Figure 144: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 145: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 146: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 147: Caris Life Sciences.: Overall Product Portfolio
- Figure 148: F. Hoffmann-La Roche Ltd: Portfolio
- Figure 149: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
- Figure 150: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
- Figure 151: F. Hoffmann-La Roche Ltd: Sales (by Region), 2019-2021
- Figure 152: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
- Figure 153: Genomic Testing Cooperative: Overall Product Portfolio
- Figure 154: Guardant Health: Overall Product Portfolio
- Figure 155: Guardant Health: Overall Financials, 2019-2021
- Figure 156: Guardant Health: Revenue (by Segment), 2019-2021
- Figure 157: Guardant Health: R&D Expenditure, 2019-2021
- Figure 158: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
- Figure 159: HTG Molecular Diagnostics, Inc.: Overall Financials, 2018-2020
- Figure 160: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2018-2020
- Figure 161: HTG Molecular Diagnostics, Inc.: R&D Expenditure, 2018-2020
- Figure 162: Illumina, Inc.: Overall Product Portfolio
- Figure 163: Illumina, Inc.: Overall Financials, 2019-2021
- Figure 164: Illumina, Inc.: Revenue (by Segment), 2019-2021
- Figure 165: Illumina, Inc.: Revenue (by Region), 2019-2021
- Figure 166: Illumina, Inc.: R&D Expenditure, 2019-2021
- Figure 167: Invitae Corporation.: Overall Product Portfolio
- Figure 168: Invitae Corporation.: Overall Financials, 2018-2020
- Figure 169: Invitae Corporation.: Revenue (by Segment), 2018-2020
- Figure 170: Invitae Corporation.: Revenue (by Region), 2019-2021
- Figure 171: Invitae Corporation.: R&D Expenditure, 2019-2021
- Figure 172: Invivoscribe, Inc.: Product Portfolio
- Figure 173: Laboratory Corporation of America Holdings.: Overall Product Portfolio
- Figure 174: Laboratory Corporation of America Holdings.: Overall Financials, 2019-2021
- Figure 175: Laboratory Corporation of America Holdings.: Revenue (by Segment), 2019-2021
- Figure 176: Laboratory Corporation of America Holdings.: Revenue (by Region), 2019-2021
- Figure 177: NanoString.: Overall Product Portfolio
- Figure 178: NanoString.: Overall Financials, $Million, 2019-2021
- Figure 179: NanoString.: Revenue (by Segment), 2019-2021
- Figure 180: NanoString.: Revenue (by Region), $Million, 2019-2021
- Figure 181: NeoGenomics Laboratories.: Overall Product Portfolio
- Figure 182: NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021
- Figure 183: NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021
- Figure 184: NeoGenomics Laboratories.: R&D Expenditure, 2019-2021
- Figure 185: Opko Health, Inc.: Overall Product Portfolio
- Figure 186: Opko Health, Inc.: Overall Financials, $Million, 2019-2021
- Figure 187: Opko Health, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 188: Opko Health, Inc.: R&D Expenditure, 2019-2021
- Figure 189: QIAGEN: Overall Product Portfolio
- Figure 190: QIAGEN: Overall Financials, $Million, 2019-2021
- Figure 191: QIAGEN: Revenue (by Segment), $Million, 2019-2021
- Figure 192: QIAGEN: Revenue (by Region), $Million, 2019-2021
- Figure 193: QIAGEN: R&D Expenditure, 2019-2021
- Figure 194: Quest Diagnostics Incorporated.: Overall Product Portfolio
- Figure 195: Quest Diagnostics Incorporated.: Overall Financials, $Million, 2019-2021
- Figure 196: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2019-2021
- Figure 197: Thermo Fisher Scientific, Inc.: Overall Product Portfolio
- Figure 198: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021
- Figure 199: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
- Figure 200: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 201: Thermo Fisher Scientific, Inc.: R&D Expenditure, 2019-2021
- Figure 202: VYANTbio.: Overall Financials, $Million, 2019-2021
- List of Tables
- Table 1: Solid Tumor Testing Technologies for Clinical Laboratories
- Table 2: Technological Trends in Solid Tumor Testing Market
- Table 3: Industry Participants' Landscape in the U.S Solid Tumor Testing Market
- Table 4: New Payment Amounts for ADLTs
- Table 5: FDA-Approved Stratification Biomarkers for Targeted Therapies in Oncology
- Table 6: Some FDA-Approved Diagnostic Biomarkers
- Table 7: Some Prognostic Biomarkers
- Table 8: Estimated Cancer Deaths in California, 2022
- Table 9: Estimated Cancer Deaths in Texas, 2022
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook